AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca secures CDSCO approval to import Durvalumab for muscle-invasive bladder cancer treatment in India.

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

Real-time updates on ASTRAZENECA PHARMA share price. Check out the detailed analysis of the company in this live blog.

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...